10:36 AM EDT, 07/09/2025 (MT Newswires) -- Connect Biopharma ( CNTB ) said Wednesday that Simcere Pharmaceutical, its exclusive licensee in China, has filed a new drug application to the National Medical Products Administration of China for human monoclonal antibody rademikibart to treat atopic dermatitis in adults and adolescents.

The company said it signed a license and collaboration deal with Simcere for rademikibart in China in 2023.

Connect Biopharma ( CNTB ) added that it is entitled to get milestone payments up to a total remaining amount of about $110 million upon the fulfillment of certain development, regulatory, and commercial requirements.

Shares of Connect Biopharma ( CNTB ) were down 4% in recent Wednesday trading.

Price: 1.10, Change: -0.04, Percent Change: -3.52